The hormone nomenclature debate: Is a name change the key to patient safety?
In the latest issue of Clinical Endocrinology News, I found an interesting article reporting a proposal to change the name of a hormone. The rationale for the proposed change was “patient safety.”
In 2009, a patient with known panhypopituitarism was admitted to a U.K. hospital for elective surgery. Diagnosis included panhypopituitarism with diabetes insipidus. The patient developed hypernatremia and volume depletion, tragically leading to pronounced hypotension and death.
The author attributes this …
